FATE Insider Trading Activity and SEC Form 4 Filings
FATE insider trading summary
Over the past 12 months, insiders at Fate Therapeutics Inc (FATE) reported 7 sales worth $336K by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $336K.
Latest FATE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 3, 2026 | Kamal Adawi | Chief Financial Officer | Sell | $14K (6,582 @ $2.05) |
| Aug 4, 2026 | Cindy Tahl | See Remarks | Sell | $95K (38,800 @ $2.46) |
| Aug 4, 2026 | Bahram Valamehr | President and CEO | Sell | $108K (43,947 @ $2.46) |
| May 20, 2026 | Bahram Valamehr | President and CEO | Sell | $54K (28,946 @ $1.88) |
| May 20, 2026 | Cindy Tahl | See Remarks | Sell | $48K (25,590 @ $1.88) |
| Jan 9, 2026 | Cindy Tahl | See Remarks | Sell | $11K (10,589 @ $1.06) |
| Jan 9, 2026 | Bahram Valamehr | President and CEO | Sell | $6K (5,190 @ $1.07) |
| Aug 4, 2025 | Bahram Valamehr | President and CEO | Sell | $15K (14,466 @ $1.06) |
| Aug 4, 2025 | Cindy Tahl | See Remarks | Sell | $10K (9,037 @ $1.06) |
| Jan 10, 2025 | Jerome Charles Bressi | See Remarks | Sell | $9K (5,980 @ $1.55) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.